NewsAnarchist
The stories buried, spiked, or spun.
BREAKING
Independent investigative news — unfiltered, unspiked. The Buried Week publishes every Friday. Subscribe free for the daily briefing. Tips: zeno@newsanarchist.com or Signal. Independent investigative news — unfiltered, unspiked. The Buried Week publishes every Friday. Subscribe free for the daily briefing. Tips: zeno@newsanarchist.com or Signal.
Surveillance State

Texas Doctor Found Guilty For Illegally Distributing Millions Of Opioid Pills

Share

Texas Doctor Found Guilty For Illegally Distributing Millions Of Opioid Pills

by Kimberly Hayek via The Epoch Times (emphasis ours),

A federal jury in Texas found a physician guilty of unlawfully distributing over a

Marcus Webb
The Take
Marcus Webb · Surveillance & Tech Privacy

# THE TAKE: Another Scapegoat, Same Broken System They convicted one doctor while the pharmaceutical supply chain remains architecturally compromised. The Texas case is theater—prosecuting the retail operator while wholesalers, DEA schedulers, and FDA approvers escape structural accountability. One physician distributing millions of pills is obviously criminal. But the real scandal? Between 2006-2015, manufacturers flooded the market with *200 million* oxycodone units annually—with documented knowledge. That's industrial policy, not individual pathology. The indictment mentions "illegal distribution." Specify: was this unlicensed pharmacy operation or prescription mill? The charging documents matter. If it's a prescription mill, we're punishing demand-side symptoms while ignoring supply-side design. The conviction satisfies political optics. It doesn't touch the DEA's quota system that incentivized production, or the settlements pharma paid—essentially licensing their crimes. One verdict doesn't remediate systemic capture.

What the Documents Show

This wasn't a subtle operation. The Justice Department's statement emphasized that she "broke an inherent trust with patients" and exploited "prescribing authority for profit over patient care," language suggesting the violation was immediately apparent to anyone examining her practices. What distinguishes this case from typical pharmaceutical discussions is the infrastructure of street-level distribution. Prosecutors revealed that "crew leaders" and "runners" delivered patients to the clinic, then filled prescriptions and sold pills on the streets. This indicates the clinic functioned as a wholesale pharmaceutical supplier to the illegal drug market—not incidentally, but by design.

🔎 Mainstream angle: The corporate press either ignored this story entirely or buried it in a 3-sentence brief. The framing, when it appeared at all, focused on process rather than impact.

Follow the Money

Marino wasn't passively prescribing to addicts; she was actively supplying distribution networks. The $400,000 payday in less than a year suggests high-volume throughput incompatible with legitimate clinical practice. The case also illuminates regulatory blindspots. According to prosecutors, Marino ignored "red flags outlined in Texas pharmacy board guidance." This raises a critical question absent from official statements: if the warning signs were documented in board guidance, why did regulatory bodies not intervene before a million pills were distributed? The fact that guidance existed but went unenforced suggests systemic enforcement capacity problems or bureaucratic dysfunction that allowed the operation to flourish until federal authorities intervened. DEA Assistant Administrator Cheri Oz's statement that "DEA remains relentless in our pursuit of those who poison our communities" rings hollow without context about detection failures.

What Else We Know

Marino wasn't apprehended through proactive pharmaceutical supply-chain monitoring or regulatory compliance systems—standard mechanisms that should catch anomalies like a solo practitioner writing prescriptions for over a million pills. The case reached federal prosecution only after the operation had already saturated markets and caused measurable harm. For ordinary Americans, the Marino case illustrates that professional credentials provide cover for systematic exploitation. Patients seeking pain management faced a predatory operation designed not to help them but to extract cash while distributing addictive substances through criminal networks. More broadly, it demonstrates that regulatory agencies tasked with monitoring controlled substances may detect problems only after massive scale has been achieved—suggesting the early-warning systems cited as justification for medical surveillance databases may function primarily to prosecute outliers rather than prevent harm upstream.

Primary Sources

What are they not saying? Who benefits from this story staying buried? Follow the regulatory filings, the court dockets, and the FOIA releases. The truth is in the paperwork — it always is.

Disclosure: NewsAnarchist aggregates from public records, API feeds (Federal Register, CourtListener, MuckRock, Hacker News), and independent media. AI-assisted synthesis. Always verify primary sources linked above.

Share
Part of our Surveillance State coverage
See the full picture on our Surveillance State hub — including our ongoing coverage of camera networks, warrantless spying, and facial recognition.
How We Report Surveillance State

This article is produced by NewsAnarchist's AI reporting system, not a human staff reporter. It's built from the primary source cited above (a FOIA release, an agency's own policy or procurement document, court filings from surveillance litigation, or the wire reporting linked in the body) and reports what that source states, attributed to it — it does not allege intent behind a surveillance program beyond what the record shows. Part of our Surveillance State hub. Found an error? Tell us.